Clinical Trials
14 trialsNCT07405151 2026-06-01
MK-3475-06F
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05319730 2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07109726 2026-05-22
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Phase 1/2 Recruiting
NCT06780111 2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07189871 2026-03-27
BetaBart
Radiopharm Theranostics, Ltd
Phase 1/2 Recruiting
NCT06747585 2026-03-03
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT07385001 2026-02-03
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
Phase 1/2 Recruiting
NCT07061704 2025-12-08
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 1/2 Recruiting
NCT05914116 2025-11-21
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT06975410 2025-08-01
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
Phase 1/2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT05473156 2025-03-26
APT-CUBE
AP Biosciences Inc.
Phase 1/2 Recruiting
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting